Vaxcyte, Inc. (PCVX) Fundamental Analysis: Bull vs. Bear Case

PCVX

Vaxcyte, Inc.

Fundamental data last updated:September 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

VALUATION

P/E

-7.58

Market Cap ($M USD)

$7.42B

Forward P/E

7.26 PEG

0.04 PRICE TO SALES

0.00 PRICE TO BOOK

2.39 EV / EBITDA

-7.69

5-Year Average P/E

Free Cash Flow Yield

-10.40%

DCF Value

$-0.57

Graham Number

N/A

Price to FCF

-9.62

EV to FCF

-9.43

Earnings Yield

-13.20%

FCF Yield

-10.40%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$6.78

Next Year EPS Growth Estimate

$7.08

Next Year Revenue Growth Estimate

$2.50B

Return on Equity (ROE)

-32.51%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.09 Piotroski F-Score

1 Altman Z-Score

10.99 Return on Invested Capital (ROIC)

-35.05%

Current Ratio

7.49 Quick Ratio

7.49 Net Debt to EBITDA

0.15 Interest Coverage

0.00 Gross Profit margin

0.00%

FCF PER SHARE

$-5.53

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

PCVX’s valuation is a paradox. Despite a staggering negative DCF value, the market has priced it with a Forward P/E of 7.49, suggesting optimism about future earnings. The Altman Z-score of 11.60 indicates robust financial health, yet the negative earnings yield and ROIC of -35.05% raise red flags about profitability. The stock’s current price, trading below its mean consensus target, hints at potential upside, but the negative Price to FCF ratio underscores cash flow concerns. Investors must weigh these contradictions carefully.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Vaxcyte is well-positioned to leverage AI for drug discovery and development. The industry's rapid adoption of AI tools could enhance efficiency and innovation. However, the company's current financial metrics suggest it must first stabilize its core operations to fully capitalize on these technological advancements.

The Bull Case

For the bullish investor, Vaxcyte's low Debt/Equity ratio of 0.085 and a high Altman Z-score suggest a fortress-like balance sheet. The Forward PEG of 0.036 signals potential undervaluation relative to growth, making it attractive for GARP investors. Despite a low Piotroski F-Score, the company's impressive sales growth forecast and strong liquidity ratios indicate resilience and potential for capital efficiency improvements.

The Bear Case

The bear case for Vaxcyte is compelling. The negative Price to FCF and earnings yield highlight severe cash flow issues, while the Piotroski F-Score of 1 signals weak operational efficiency. Trading near its 52-week high, the stock appears technically overextended. The lack of profitability, with a negative EPS and ROIC, further underscores the structural risks that could deter cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$89.00

Institutional Ownership %

1-Year Beta

1.30 Insider Buying % (6 Mo)

Distance to 52-Week High

26.46%

Distance to 52-Week Low

43.42%

EARNINGS SURPRISE %

-29.65%

50-DAY SMA

$56.12

200-DAY SMA

$47.88

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.